Scorpion Stings Harmony with Citizen’s Petition Threat for Sleepiness Drug 3/29/2023

Positive Phase III Builds Case for Intra-Cellular's Depression Drug 3/29/2023

Viking Enters Weight-Loss Arena with Promising Phase I Data 3/29/2023

Covant Therapeutics Debuts with Boehringer Partnership Targeting ADAR1 3/29/2023

Malignant melanoma is a relatively aggressive type of skin cancer. When detected early, it is usually treatable by surgical resection only, but metastases develop often spreading to distant areas. Currently, tumor thickness and the presence of ulceration are some of the known prognostic factors used as indicators of malignant melanoma. Therefore, the discovery of valuable markers to assess the malignant potential of melanoma more accurately may be necessary to develop appropriate treatments.

Keytruda Maintains Edge over GSK’s Jemperli in Endometrial Cancer (Updated) 3/28/2023

Bicycle, Novartis Ink Oncology Deal Worth up to $1.7B 3/28/2023

Evotec Up for Potential $4B More in Lucrative BMS Partnership 3/28/2023

Monopar Drops Lead Candidate after Disappointing Phase III Analysis 3/28/2023

Novartis presented new data which underscore the transformational and sustained benefit of Zolgensma® (onasemnogene abeparvovec), an essential one-time gene therapy for the treatment of spinal muscular atrophy (SMA). Latest data from two Long-Term Follow-Up (LTFU) studies, LT-001 and LT-002, show the continued efficacy and durability of Zolgensma across a range of patient populations, with an overall benefit-risk profile that remains favorable.

Novartis' Kisqali Cuts Recurrence Risk in Early-Stage Breast Cancer 3/27/2023

ArriVent Snags $155M for NSCLC Treatment in Record Low Series B Period 3/27/2023

UNITY Shares Nearly Halved after Lead Asset Fails to Match Regeneron’s Eylea 3/27/2023

5 High-Paying Life Science Jobs that Don't Include Management 3/27/2023

BrainStorm Secures FDA Adcomm for ALS Therapy NurOwn 3/27/2023

Pharming’s Leniolisib Gains FDA Approval in Ultra-Rare Disease 3/27/2023

Relmada Looks to Rebound with New Protocol After Two Phase III Flops 3/27/2023

FDA Action Alert: Roche, Emergent and More 3/27/2023

Researchers have developed a molecule that is, when administered nasally, extremely effective in preventing the disease caused by all known variants of the SARS-CoV-2 virus. The molecule can be a key tool in preparing for future pandemics, as it is aimed at preventing both the transmission and spread of the virus.

In laboratory animal studies, a molecule known as TriSb92, developed by researchers at the University of Helsinki, has been confirmed as affording effective protection against coronavirus infection.

Latest Data for Karuna’s Schizophrenia Drug Spark Investor Concern 3/24/2023